Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.
Portfolio Pulse from
Eli Lilly's drugs Zepbound and Mounjaro have missed sales estimates for the second consecutive time, raising concerns about their market performance in the obesity and Type 2 diabetes sectors.
January 14, 2025 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's Zepbound and Mounjaro drugs have missed sales estimates for the second time in a row, indicating potential challenges in the obesity and Type 2 diabetes markets.
The repeated sales miss for Zepbound and Mounjaro suggests potential issues in market penetration or competition, which could negatively impact Eli Lilly's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100